Androgen Deprivation Therapy And Morbid Obesity: Do They Share Cardiovascular Risk Through Metabolic Syndrome? [terapia De Privación De Andrógenos Y Obesidad Mórbida: ¿tienen En Común El Riesgo Cardiovascular Por Síndrome Metabólico?]

dc.creatorCleffi S.
dc.creatorNeto A.S.
dc.creatorReis L.O.
dc.creatorMaia P.
dc.creatorFonseca F.
dc.creatorWroclawski M.L.
dc.creatorNeves M.
dc.creatorPompeo A.C.L.
dc.creatorDel Giglio A.
dc.creatorFaria E.F.
dc.creatorTobias-Machado M.
dc.date2011
dc.date2015-06-30T20:37:58Z
dc.date2015-11-26T14:52:23Z
dc.date2015-06-30T20:37:58Z
dc.date2015-11-26T14:52:23Z
dc.date.accessioned2018-03-28T22:04:26Z
dc.date.available2018-03-28T22:04:26Z
dc.identifier
dc.identifierActas Urologicas Espanolas. , v. 35, n. 5, p. 259 - 265, 2011.
dc.identifier2104806
dc.identifier10.1016/j.acuro.2011.01.011
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-79955141565&partnerID=40&md5=635d7e3aae0d3cac20e16929f0400509
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/108709
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/108709
dc.identifier2-s2.0-79955141565
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1254809
dc.descriptionBackground: Although the use of androgen deprivation therapy (ADT) has resulted in improved survival in men with advanced prostate cancer, the resulting hypogonadism is associated with profound adverse effects comparable to those found in morbid obesity, being cardiovascular risk among the most lethal. Objectives: Evaluate metabolic syndrome, metabolic abnormalities and cardiovascular risk in patients with prostate cancer under ADT, not under ADT and morbid obese men. Methods: This is a cross-sectional study that involves 79 men presenting prostate cancer, of whom 54 under ADT and 25 not under ADT and 91 morbidly obese patients paired by sex and age. To define metabolic syndrome, we used the International Diabetes Federation (IDF) criteria. Metabolic abnormalities, metabolic markers and Framingham score to predict the ten year coronary heart disease risk were compared among patients under ADT, not under ADT and morbid obese. Results: Patients under ADT presented significantly greater occurrence of diabetes and central obesity and higher levels of total cholesterol and low density lipoprotein (LDL) compared to eugonadal men. The mean cardiovascular risk was significantly higher in patients under ADT (39.97 ± 12.53% vs. 26.09 ± 14.80%; p = 0.021). Morbidly obese subjects had increased ten year coronary heart disease risk; comparable to patients under ADT (p = 0.054). Conclusion: This study suggests that patients under ADT show higher prevalence of metabolic abnormalities and cardiovascular risk similar to those found in morbidly obese subjects. It is possible that both processes share cardiovascular risk through metabolic syndrome. © 2010 AEU. Published by Elsevier España, S.L. All rights reserved.
dc.description35
dc.description5
dc.description259
dc.description265
dc.descriptionReis, L.O., Sasse, A.D., Matheus, W.E., Denardi, F., Stopiglia, R.M., Da Silva, M.M., Prostate cancer: Evidence based clinical practice (2009) Actas Urol Esp., 33, pp. 344-350
dc.descriptionGugliotta, A., Ferreira, U., Reis, L.O., Matheus, W.E., Denardi, F., Mamprim Stopiglia, R., Satisfaction analysis in men presenting with localized prostate cancer treated with radical prostatectomy or radiotherapy: Psychological and social aspects (2008) Actas Urol Esp., 32, pp. 411-416
dc.descriptionHuggins, C., Stevens Jr., R.F., Hodges, C.V., Studies on prostatic cancer. The effects of castration on advanced carcinoma of prostate gland (1941) Arch Surg., 43, pp. 209-223
dc.descriptionHakimian, P., Blute Jr., M., Kashanian, J., Chan, S., Silver, D., Shabsigh, R., Metabolic and cardiovascular effects of androgen deprivation therapy (2008) BJU Int., 102, pp. 1509-1514
dc.descriptionBasaria, S., Dobs, A.S., Hypogonadism and androgen replacement therapy in elderly men (2001) Am J Med., 110, pp. 563-572
dc.descriptionBasaria, S., Lieb II, J., Tang, A.M., DeWeese, T., Carducci, M., Eisenberger, M., Dobs, A.S., Long-term effects of androgen deprivation therapy in prostate cancer patients (2002) Clinical Endocrinology, 56 (6), pp. 779-786. , DOI 10.1046/j.1365-2265.2002.01551.x
dc.descriptionStellato, R.K., Feldman, H.A., Hamdy, O., Horton, E.S., Mckinlay, J.B., Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts Male Aging Study (2000) Diabetes Care, 23 (4), pp. 490-494
dc.descriptionReaven, G.M., Role of insulin resistance in human disease (1988) Diabetes, 37 (12), pp. 1595-1607
dc.descriptionD'Amico, A.V., Whittington, R., Bruce Malkowicz, S., Schultz, D., Blank, K., Broderick, G.A., Tomaszewski, J.E., Wein, A., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer (1998) Journal of the American Medical Association, 280 (11), pp. 969-974. , DOI 10.1001/jama.280.11.969
dc.description(2005) Consensus Worldwide Definition of the Metabolic Syndrome, , www.idf.org/metabolic_syndrome, International Diabetes Federation (IDF) Disponible en:
dc.descriptionAnderson, K.M., Wilson, P.W., Odell, P.M., Kannel, W.B., An updated coronary risk profile. A statement for health professionals (1991) Circulation., 83, pp. 356-362
dc.descriptionWilson, P.W.F., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B., Prediction of coronary heart disease using risk factor categories (1998) Circulation, 97 (18), pp. 1837-1847
dc.descriptionCarroll, P.M., Early stage prostate cancer - Do we have a problem with over-detection, overtreatment or both? (2005) Journal of Urology, 173 (4), pp. 1061-1062. , DOI 10.1097/01.ju.0000156838.67623.10
dc.descriptionSaigal, C.S., Gore, J.L., Krupski, T.L., Hanley, J., Schonlau, M., Litwin, M.S., Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer (2007) Cancer, 110 (7), pp. 1493-1500. , DOI 10.1002/cncr.22933
dc.descriptionGlode, L.M., Metabolic syndrome and prostate cancer (2008) Cancer, 112 (10), pp. 2103-2105. , DOI 10.1002/cncr.23511
dc.descriptionBasaria, S., Muller, D.C., Carducci, M.A., Egan, J., Dobs, A.S., Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy (2006) Cancer, 106 (3), pp. 581-588. , DOI 10.1002/cncr.21642
dc.descriptionSmith, M., Lee, H., Nathan, D., Insulin sensitivity during combined androgen blockade for prostate cancer (2006) J Clin Endocrinol Metab., 91, pp. 1305-1308
dc.descriptionBraga-Basaria, M., Muller, D.C., Carducci, M.A., Dobs, A.S., Basaria, S., Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy (2006) International Journal of Impotence Research, 18 (5), pp. 494-498. , DOI 10.1038/sj.ijir.3901471, PII 3901471
dc.descriptionYannucci, J., Manola, J., Garnick, M.B., Bhat, G., Bubley, G.J., The Effect of Androgen Deprivation Therapy on Fasting Serum Lipid and Glucose Parameters (2006) Journal of Urology, 176 (2), pp. 520-525. , DOI 10.1016/j.juro.2006.03.057, PII S0022534706008342
dc.descriptionKeating, N.L., O'Malley, A.J., Smith, M.R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer (2006) Journal of Clinical Oncology, 24 (27), pp. 4448-4456. , DOI 10.1200/JCO.2006.06.2497
dc.descriptionTraish, A.M., Saad, F., Guay, A.T., The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance (2009) J Androl., 30, pp. 23-32
dc.descriptionKim, J., Montagnani, M., Koh, K., Quon, M., Reciprical relationships between insulin resistance and endothelial dysfunction (2006) Circulation., 113, pp. 1888-1904
dc.descriptionMancini, A., Milardi, D., Bianchi, A., Summaria, V., De Marinis, L., Increased estradiol levels in venous occlusive disorder: A possible functional mechanism of venous leakage (2005) International Journal of Impotence Research, 17 (3), pp. 239-242. , DOI 10.1038/sj.ijir.3901287
dc.descriptionMakhsida, N., Shah, J., Yan, G., Fisch, H., Shabsigh, R., Hypogonadism and metabolic syndrome: Implications for testosterone therapy (2005) Journal of Urology, 174 (3), pp. 827-834. , DOI 10.1097/01.ju.0000169490.78443.59
dc.descriptionZumoff, B., Miller, L.K., Strain, G.W., Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone (2003) Metabolism: Clinical and Experimental, 52 (9), pp. 1126-1128. , DOI 10.1016/S0026-0495(03)00186-0
dc.descriptionPitteloud, N., Hardin, M., Dwyer, A.A., Valassi, E., Yialamas, M., Elahi, D., Hayes, F.J., Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men (2005) Journal of Clinical Endocrinology and Metabolism, 90 (5), pp. 2636-2641. , DOI 10.1210/jc.2004-2190
dc.descriptionReis, L.O., Favaro, W.J., Barreiro, G.C., De Oliveira, L.C., Chaim, E.A., Fregonesi, A., Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: A prospective randomized controlled trial (2010) Int J Androl., 33, pp. 736-744
dc.descriptionReis, L.O., Pereira, T.C., Lopes-Cendes, I., Ferreira, U., MicroRNAs: A new paradigm on molecular urological oncology (2010) Urology., 76, pp. 521-527
dc.descriptionReis, L.O., Vieira, L.F., Zani, E.L., Denardi, F., De Oliveira, L.C., Ferreira, U., Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer (2010) J Investig Med., 58, pp. 957-960
dc.languagees
dc.publisher
dc.relationActas Urologicas Espanolas
dc.rightsfechado
dc.sourceScopus
dc.titleAndrogen Deprivation Therapy And Morbid Obesity: Do They Share Cardiovascular Risk Through Metabolic Syndrome? [terapia De Privación De Andrógenos Y Obesidad Mórbida: ¿tienen En Común El Riesgo Cardiovascular Por Síndrome Metabólico?]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución